ERBB2 and cancer: Of the 92 invasive breast cancers in this study, 21 (22.8%) were luminal A cancer, 30 (32.6%) were luminal B cancer, 33 (35.9%) were HER2-positive cancer, and 8 (8.7%) were triple-negative cancer.